Canaccord Genuity Reiterates Hold Rating for AxoGen (NASDAQ:AXGN)
AxoGen (NASDAQ:AXGN)‘s stock had its “hold” rating reiterated by equities researchers at Canaccord Genuity in a note issued to investors on Wednesday, AnalystRatings.com reports. They presently have a $13.00 target price on the medical equipment provider’s stock. Canaccord Genuity’s target price would indicate a potential downside of 0.46% from the stock’s current price.
A number of other equities research analysts have also issued reports on the stock. SVB Leerink upped their target price on shares of AxoGen from $13.50 to $15.50 and gave the stock an “outperform” rating in a report on Thursday, August 6th. BTIG Research reissued a “hold” rating on shares of AxoGen in a report on Wednesday, August 5th. BidaskClub lowered shares of AxoGen from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, Cantor Fitzgerald began coverage on shares of AxoGen in a report on Monday, June 15th. They issued a “buy” rating and a $16.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $16.38.
Shares of AxoGen stock traded up $2.31 during trading hours on Wednesday, reaching $13.06. 11,017 shares of the company’s stock were exchanged, compared to its average volume of 219,863. AxoGen has a 1 year low of $7.16 and a 1 year high of $18.84. The company has a market capitalization of $425.69 million, a P/E ratio of -17.89 and a beta of 0.74. The business has a fifty day moving average of $11.47 and a two-hundred day moving average of $10.18. The company has a quick ratio of 9.09, a current ratio of 10.00 and a debt-to-equity ratio of 0.27.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers boosted its stake in AxoGen by 2.3% during the first quarter. Rhumbline Advisers now owns 46,125 shares of the medical equipment provider’s stock worth $480,000 after buying an additional 1,030 shares during the period. M&T Bank Corp boosted its stake in AxoGen by 7.3% during the second quarter. M&T Bank Corp now owns 18,984 shares of the medical equipment provider’s stock worth $175,000 after buying an additional 1,284 shares during the period. Swiss National Bank boosted its stake in AxoGen by 1.9% during the first quarter. Swiss National Bank now owns 68,900 shares of the medical equipment provider’s stock worth $717,000 after buying an additional 1,300 shares during the period. Mitsubishi UFJ Trust & Banking Corp boosted its stake in AxoGen by 0.4% during the first quarter. Mitsubishi UFJ Trust & Banking Corp now owns 384,380 shares of the medical equipment provider’s stock worth $3,998,000 after buying an additional 1,560 shares during the period. Finally, American International Group Inc. boosted its stake in AxoGen by 10.8% during the second quarter. American International Group Inc. now owns 22,257 shares of the medical equipment provider’s stock worth $206,000 after buying an additional 2,177 shares during the period. 79.29% of the stock is owned by hedge funds and other institutional investors.
AxoGen Company Profile
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Recommended Story: What is the Consumer Price Index (CPI)?
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.